<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02437461</url>
  </required_header>
  <id_info>
    <org_study_id>TW77</org_study_id>
    <nct_id>NCT02437461</nct_id>
  </id_info>
  <brief_title>Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis</brief_title>
  <official_title>Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective randomised controlled single blind trial comparing the relapse rate in 6
      months for 20 mg versus 40 mg intraarticular triamcinolone hexacetonide (Lederspan®) for knee
      synovitis in patients with rheumatoid arthritis (RA) and psoriatic artritis (PsoA) is
      performed to find the optimal dose to use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Triamcinolone hecacetonide (THA) has been used for local intraarticular injecton treatment
      for knee synovitis in decades, but no dose finding studies have been performed. In the
      literature the doses for knee injections vary between 20 mg and 80 mg, depending on local
      traditions.

      The aim of the present study is to find the optimal THA dosing, comparing the relapse rate
      during a 6 month observation period for the two most used dosages .

      Methods:

      Adult patients with RA or PsoA with treatment demands for ongoing knee synovitis are
      recruited at the Rheumatology Departments in Gävle and Falun. After informed consent patient
      characteristics,(age, sex, medical treatment), clinical and laboratory parameters of disease
      activity (DAS28, CRP), as well as degree of functional impairment (HAQ) are collected. A
      radiographic examination of the knee is performed and assessed (using Larsen Dale index) by
      an independent radiologist. The patients are allocated to either 20 mg or 40 mg THA using the
      randomisation dose which is hidden in prepared closed envelopes. After complete synovial
      fluid aspiration the THA dose is injected . The patients are told to contact the rheumatology
      department if no treatment response or if symtoms from the treated knee recurr. If so, the
      knee is examined again and if synovitis is confirmed a relapse is registered. Time from
      injection to relapse is calculated. Patients without relapse are called after 6 months to
      confirm they still are well and that no unknown relapse have occurred. When the observation
      period for the last included patient is finished the relapse rate between the 20 mg THA group
      is compared with the 40 mg THA Group.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">June 20, 2018</completion_date>
  <primary_completion_date type="Actual">September 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>arthritis relapse</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Arthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>single dose 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraarticular injection of triamcinolone hexacetonide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single dose 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraarticular injection of triamcinolone hexacetonide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone hexacetonide</intervention_name>
    <description>intraarticular knee injection</description>
    <arm_group_label>single dose 20 mg</arm_group_label>
    <arm_group_label>single dose 40 mg</arm_group_label>
    <other_name>Lederspan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: synovitis of the knee, rheumatoid arthritis or psoriatic arthrthritis,
        written informed consent

        Exclusion Criteria:

          -  inability to understand study information, function class 4 according to Steinbrocker,
             planning knee surgery, , joint infection, intraarticular glucocorticoid injection in
             this joint the past 3 months, oral glucocortoid treatment corresponding to &gt;10 mg
             prednisolone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Weitoft, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Research and Development Uppsala University/Region Gavleborg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Section of Rheumatology, Gävle hospital</name>
      <address>
        <city>Gavle</city>
        <zip>80187</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Weitoft T, Uddenfeldt P. Importance of synovial fluid aspiration when injecting intra-articular corticosteroids. Ann Rheum Dis. 2000 Mar;59(3):233-5.</citation>
    <PMID>10700435</PMID>
  </reference>
  <reference>
    <citation>Lopes RV, Furtado RN, Parmigiani L, Rosenfeld A, Fernandes AR, Natour J. Accuracy of intra-articular injections in peripheral joints performed blindly in patients with rheumatoid arthritis. Rheumatology (Oxford). 2008 Dec;47(12):1792-4. doi: 10.1093/rheumatology/ken355. Epub 2008 Sep 27.</citation>
    <PMID>18820311</PMID>
  </reference>
  <reference>
    <citation>Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995 Jan;38(1):44-8.</citation>
    <PMID>7818570</PMID>
  </reference>
  <reference>
    <citation>Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol. 1988;17(4):263-71.</citation>
    <PMID>3187457</PMID>
  </reference>
  <reference>
    <citation>Weitoft T, Rönnelid J, Knight A, Lysholm J, Saxne T, Larsson A. Outcome predictors of intra-articular glucocorticoid treatment for knee synovitis in patients with rheumatoid arthritis - a prospective cohort study. Arthritis Res Ther. 2014 Jun 20;16(3):R129. doi: 10.1186/ar4586.</citation>
    <PMID>24950951</PMID>
  </reference>
  <reference>
    <citation>Larsen A, Dale K. Standardized radiological examination of rheumatoid arthritis in therapeutical trials. In Dumonde DC, Jasani MK, eds. The recognition of antirheumatic drugs. Lancaster: MTP Press, 1978: 285-292</citation>
  </reference>
  <reference>
    <citation>Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315-24.</citation>
    <PMID>3358796</PMID>
  </reference>
  <reference>
    <citation>Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-73.</citation>
    <PMID>16871531</PMID>
  </reference>
  <reference>
    <citation>STEINBROCKER O, TRAEGER CH, BATTERMAN RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949 Jun 25;140(8):659-62.</citation>
    <PMID>18150288</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University</investigator_affiliation>
    <investigator_full_name>Thomas Weitoft</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>knee synovitis</keyword>
  <keyword>triamcinolone hexacetonide</keyword>
  <keyword>treatment response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Synovitis</mesh_term>
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

